ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

ASCO Seeks “Nothing Less Than A Smoke-Free World”

June 6, 2003

Niederhuber To Stay at NCI While Obama Makes NIH Plans

January 23, 2009

Also in this 8-page issue: John Niederhuber joins NCI as special advisor, quits NCAB. Harold Freeman steps down as NCI disparities head.

September 9, 2005

High-Priority Radiation Therapy Research Projects Approved By DCT Board of Counselors

March 26, 1976

ACCC Recommends Cancer Act Changes

August 27, 1976

NCI Begins TAILORx Study.

May 26, 2006